PARP1 and retinitis pigmentosa 1: We employed the recently generated human homologous RhoI255del knock‐in mouse model for dominant RP (Cao, Dahlen, et al. 2024; Cao, Zhu, et al. 2024; Zhu, Kumar, et al. 2025; Zhu, Peiroten, et al. 2025) to test different PARP inhibitors for potential neuroprotective effects.